FOXO1-IN-3_product_DataBase

Bioactivity

FOXO1-IN-3 is a highly-selective and orally active FOXO1 inhibitor. FOXO1-IN-3 reduces hepatic glucose production in mice. FOXO1-IN-3 improves insulin sensitivity and glucose control in db/db mice without causing weight gain[1].

Target

FOXO1

Invitro

FOXO1-IN-3 (Compound 10) (10 μM，6 小时) 抑制正常小鼠原代肝细胞中 cAMP/Dexamethasone (HY-14648) 诱导的 G6pc 和 Pck1 mRNA 表达[1]。 RT-PCRsup>[1] Cell Line:

In Vivo

FOXO1-IN-3 (Compound 10) (16 mg/kg，口服，每天两次，持续 10 天) 可降低 db/db 小鼠的血糖[1]。FOXO1-IN-3 (16 mg/kg，口服，每天两次，持续 7 天) 和 FGF21 (0.45 mg/kg) 在 Streptozotocin (HY-13753) 诱导的 β 细胞消除糖尿病小鼠中具有协同降糖作用[1]。FOXO1-IN-3 (静脉注射 1 mg/kg，口服 10 mg/kg) 在小鼠中显示出显着的血浆暴露和口服生物利用度，尽管中的半衰期相对较短[1]。 Animal Model:

Name

FOXO1-IN-3

CAS

2451093-95-9

Formula

C22H23N7O

Molar Mass

401.46

Appearance

Solid

Transport

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Reference

[1]. Lee YK, et al. FOXO1 inhibition synergizes with FGF21 to normalize glucose control in diabetic mice. Mol Metab. 2021 Jul;49:101187.

PeptideDB

FOXO1-IN-3

CAS: 2451093-95-9 F: C22H23N7O W: 401.46